Apixaban ( DrugBank: Apixaban )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
96クローン病1
97潰瘍性大腸炎1
222一次性ネフローゼ症候群2

96. クローン病


臨床試験数 : 2,400 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03935451
(ClinicalTrials.gov)
September 1, 202123/4/2019Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel DiseaseA Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot StudyIBD;Venous Thromboembolism;Crohn Disease;Ulcerative Colitis;Pulmonary Embolism;Colorectal DisordersDrug: Apixaban 2.5 milligram;Drug: Placebo Oral TabletMcMaster UniversityNULLRecruiting18 YearsN/AAll60Early Phase 1Canada

97. 潰瘍性大腸炎


臨床試験数 : 2,527 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03935451
(ClinicalTrials.gov)
September 1, 202123/4/2019Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel DiseaseA Randomized Controlled Trial on the Use of Postoperative Extended Venous Thromboprophylaxis in Patients With Inflammatory Bowel Disease: A Pilot StudyIBD;Venous Thromboembolism;Crohn Disease;Ulcerative Colitis;Pulmonary Embolism;Colorectal DisordersDrug: Apixaban 2.5 milligram;Drug: Placebo Oral TabletMcMaster UniversityNULLRecruiting18 YearsN/AAll60Early Phase 1Canada

222. 一次性ネフローゼ症候群


臨床試験数 : 285 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04278729
(ClinicalTrials.gov)
April 14, 202118/2/2020A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic SyndromeA Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic SyndromeNephrotic Syndrome;Membranous NephropathyDrug: Apixaban 5 MGUniversity of North Carolina, Chapel HillAmerican College of Clinical PharmacyRecruiting18 Years79 YearsAll30Phase 1United States
2EUCTR2019-001212-29-DK
(EUCTR)
26/08/202009/06/2020Causes and prevention of thrombosis developed due to the kidney disease nephrotic syndromeCauses and Prevention of Thromboembolic Disease in Nephrotic Syndrome Nephrotic syndrome is defined as severe proteinuria (> 0.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of a large number of plasma proteins including coagulation factors and consequently a increased risk of thromboembolic complications. The most frequent cause of nephrotic syndrome is the renal disease membranous nephropathy, which is associated with the greatest risk of thromboembolic complications.
MedDRA version: 21.1;Level: LLT;Classification code 10029167;Term: Nephrotic syndrome with lesion of membranous glomerulonephritis;System Organ Class: 100000004857
MedDRA version: 20.0;Classification code 10029165;Term: Nephrotic syndrome in diseases classified elsewhere;System Organ Class: 100000004857;Therapeutic area: Not possible to specify
Trade Name: Fragmin
INN or Proposed INN: Dalteparin
Other descriptive name: Dalteparin
Trade Name: Eliquis
INN or Proposed INN: Apixaban
Other descriptive name: Apixaban
Aarhus University Hospital, Henrik BirnNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 1;Phase 2Denmark